Article
Cardiac & Cardiovascular Systems
Yu-Wen Lin, Chi-Chuan Wang, Chau-Chung Wu, Yih-Ting Hsu, Fang-Ju Lin
Summary: This study found that statin use in elderly individuals without a history of cardiovascular disease can reduce the risk of cardiovascular events and mortality.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Gil Lavie, Moshe Hoshen, Morton Leibowitz, Arriel Benis, Amichay Akriv, Ran Balicer, Orna Reges
Summary: This study found that the use of statins for primary prevention of cardiovascular disease in adults over 70 years old is beneficial and does not increase the risk of diabetes. However, for individuals under 70 years old, the risk-benefit ratio of statin therapy is less favorable compared to the older group.
AMERICAN JOURNAL OF MEDICINE
(2021)
Article
Health Care Sciences & Services
Ashish Sarraju, Gabriela Spencer-Bonilla, Sukyung Chung, Sofia Gomez, Jiang Li, Paul Heidenreich, Latha Palaniappan, Fatima Rodriguez
Summary: This retrospective cohort study examined statin treatment patterns and incident ASCVD among older adults aged 65-79 for primary prevention. It found that patients over 75 years old were less likely to receive moderate- or high-intensity statin prescriptions, and had a higher risk of incident ASCVD compared to younger counterparts. Further research is needed to understand the reasons for age-based differences in statin use and ASCVD risk among older adults.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Maria Bergami, Edina Cenko, Jinsung Yoon, Guiomar Mendieta, Sasko Kedev, Marija Zdravkovic, Zorana Vasiljevic, Davor Milicic, Olivia Manfrini, Mihaela van der Schaar, Chris P. Gale, Lina Badimon, Raffaele Bugiardini
Summary: Preventive statin therapy in the elderly reduces the risk of ST-segment elevation myocardial infarction (STEMI) and has benefits in mortality, regardless of the presence of hypercholesterolemia history. This effect persists after the age of 76 years, but the benefits are less pronounced in women.
CARDIOVASCULAR RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Yongin Cho, Yujin Jeong, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, Young Ju Suh, So Hun Kim
Summary: The study found that in elderly Asian patients without clinically recognized atherosclerotic cardiovascular disease (CVD), statin treatment significantly reduced the risk of cardiovascular mortality and was associated with a reduction in ischemic stroke in patients with diabetes.
Article
Cardiac & Cardiovascular Systems
Jackie Bosch, Eva M. Lonn, Hyejung Jung, Jun Zhu, Lisheng Liu, Patricio Lopez-Jaramillo, Prem Pais, Denis Xavier, Rafael Diaz, Gilles Dagenais, Antonio Dans, Alvaro Avezum, Leopoldo S. Piegas, Alexander Parkhomenko, Kati Keltai, Matyas Keltai, Karen Sliwa, Claus Held, Ronald J. G. Peters, Basil S. Lewis, Petr Jansky, Khalid Yusoff, Kamlesh Khunti, William D. Toff, Christopher M. Reid, John Varigos, Philip Joseph, Lawrence A. Leiter, Salim Yusuf
Summary: Rosuvastatin significantly reduced major adverse cardiovascular events in participants with intermediate cardiovascular risk compared to placebo. The benefits of rosuvastatin continued to increase during post-trial observation period, while blood pressure lowering did not affect the overall study outcomes.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Jackie Bosch, Eva M. Lonn, Hyejung Jung, Jun Zhu, Lisheng Liu, Patricio Lopez-Jaramillo, Prem Pais, Denis Xavier, Rafael Diaz, Gilles Dagenais, Antonio Dans, Alvaro Avezum, Leopoldo S. Piegas, Alexander Parkhomenko, Kati Keltai, Matyas Keltai, Karen Sliwa, Claus Held, Ronald J. G. Peters, Basil S. Lewis, Petr Jansky, Khalid Yusoff, Kamlesh Khunti, William D. Toff, Christopher M. Reid, John Varigos, Philip Joseph, Lawrence A. Leiter, Salim Yusuf
Summary: Rosuvastatin (10 mg daily) reduced major adverse cardiovascular events by 24% compared to placebo in participants at intermediate cardiovascular risk. The benefits of rosuvastatin continued to accrue for at least 3 years after cessation of treatment, indicating a legacy effect.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Morten Malmborg, Michelle D. S. Schmiegelow, Thomas Gerds, Morten Schou, Caroline Kistorp, Christian Torp-Pedersen, Gunnar Gislason
Summary: This study demonstrates that primary prevention with statins can reduce the risk of cardiovascular events or death in low-risk patients with T2D, with the greatest benefit seen in elderly patients and those with high adherence to statin treatment.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Geriatrics & Gerontology
Ariela R. Orkaby, Bing Lu, Yuk-Lam Ho, Timothy Treu, Ashley Galloway, Peter W. F. Wilson, Kelly Cho, J. Michael Gaziano, Karen P. Alexander, David R. Gagnon, Luc Djousse, Daniel E. Forman, Jane A. Driver
Summary: This study examined the impact of statin use on mortality and cardiovascular events in frail older adults. The results showed that statin use was associated with a lower risk of all-cause mortality and major adverse cardiovascular events, regardless of frailty.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2023)
Review
Cardiac & Cardiovascular Systems
Mahmoud Al Rifai, Roger S. Blumenthal, Neil J. Stone, Richard S. Scho, Carl Edward Orringer, Erin D. Michos, Paul A. Heidenreich, Lynne Braun, Kim K. Birtcher, Sidney C. Smith, Vijay Nambi, Scott Grundy, Salim S. Virani
Summary: This review compares the cholesterol guidelines of two major American organizations and reviews the evidence base used to generate recommendations focusing on 4 themes. The different conclusions reached by the two organizations on key issues are discussed.
PROGRESS IN CARDIOVASCULAR DISEASES
(2021)
Article
Psychiatry
Stephanie A. Hooker, Patrick J. O'Connor, Joann M. Sperl-Hillen, A. Lauren Crain, Kris Ohnsorg, Sheryl Kane, Rebecca Rossom
Summary: This study found that individuals with a diagnosis of depression and clinically significant depressive symptoms have a higher cardiovascular risk. In preventing cardiovascular diseases in individuals with depression, it is important to focus on treating depressive symptoms as well as specific uncontrolled cardiovascular risk factors.
JOURNAL OF PSYCHOSOMATIC RESEARCH
(2022)
Article
Public, Environmental & Occupational Health
Lily D. Yan, Jean Lookens Pierre, Vanessa Rouzier, Michel Theard, Alexandra Apollon, Stephano St Preux, Justin R. Kingery, Kenneth A. Jamerson, Marie Deschamps, Jean W. Pape, Monika M. Safford, Margaret L. McNairy
Summary: In this study conducted in Haiti, six existing cardiovascular disease (CVD) risk prediction models were compared, showing significant variation in identifying high-risk groups and statin eligibility. The findings suggest a need to develop and validate CVD risk prediction tools for low-middle income countries that incorporate locally relevant risk factors. The results have important implications for making appropriate treatment recommendations and public health policies.
Article
Peripheral Vascular Disease
In-Chang Hwang, Chee Hae Kim, Jae-Young Kim, Hong-Mi Choi, Yeonyee E. Yoon, Goo-Yeong Cho
Summary: The incremental 10-year risk of atherosclerotic cardiovascular disease (ASCVD) is associated with the risk of future ASCVD events, indicating the success or failure in controlling major cardiovascular risk factors. Effective control of risk factors leads to lower ASCVD event rates, whereas failure to control these risk factors results in higher ASCVD event rates.
Review
Medicine, General & Internal
Kamal Awad, Maged Mohammed, Mahmoud Mohamed Zaki, Abdelrahman I. Abushouk, Gregory Y. H. Lip, Michael J. Blaha, Carl J. Lavie, Peter P. Toth, J. Wouter Jukema, Naveed Sattar, Maciej Banach
Summary: Statin therapy in older people for primary prevention of cardiovascular disease is associated with significantly lower risks of all-cause mortality, CVD death, and stroke, but not with myocardial infarction. The observational findings support the need for further trials to test the benefits of statins in individuals above 75 years of age.
Article
Multidisciplinary Sciences
Ji Bak Kim, Woo Hyuk Song, Jong Sung Park, Tae-Jin Youn, Yong Hyun Park, Shin-Jae Kim, Sung Gyun Ahn, Joon-Hyung Doh, Yun-Hyeong Cho, Jin Won Kim
Summary: In high-risk Asian patients with hypercholesterolemia, atorvastatin 20 mg was more effective in reducing LDL-C and more cost-effective compared to atorvastatin 10 mg.
